Maureen Lacy, PhD

Education & Training

• Doctorate, Illinois Institute of Technology, 1995
• University of Michigan, Fellowship Program, 1996

Clinical Interests

• Dr. Lacy’s main clinical and research interest is in assessing the neurocognitive aspects (i.e., memory, attention, problem solving, & language) of neurologic, psychiatric and medical conditions.
  • Degenerative dementias: Alzheimer, Parkinson, MSA, Frontal Temporal Dementia, & Primary
  • Progressive Aphasia
  • Epilepsy (pre and post resection) with WADAs evaluations
  • Normal Pressure Hydrocephalus (pre and post drain trials and shunt evaluations)
  • Stroke & other Cerebral Vascular Disorders (i.e., CADASIL)
  • Psychiatric Disorders: Attention Deficit Disorders; Learning Disabilities, & Depression
  • Oncology: Brain Tumors & Breast Cancer (with Chemotherapy related issues)
  • Traumatic Brain Injury & Concussion
  • Autoimmune Diseases: Lupus, Graves, MS

Research Interests

• Dr. Lacy’s primary research focus in on understanding and treating the acute and longstanding cognitive deficits related to increased intracranial pressure (i.e., hydrocephalus).
  • Congenital Hydrocephalus
  • Aqueductal Stenosis
  • Normal Pressure Hydrocephalus
  • Chiari Malformations

Grants

• Principle Investigator (HRSA: Graduate  Psychology Education grant)
  Multidisciplinary Training Program: training interns in multidisciplinary clinics providing care for underserved clients
• Co-Investigator (Dr. David Frim)
  Intracranial pressure and Neurocognition , NIH
  Neurocognition in Chiari Malformation, Chiari Foundation
• Principle Investigator
  A 24-Week, Multicenter, Double-Blind, Randomized, Parallel-Group, Dose Ranging Study of the Efficacy and Safety of oral doses of AVE 1625 5, 10, and 30 mg and placebo on top of an established treatment regimen of either olanzapine, risperidone or quetiapine monotherapy in the treatment of Cognitive Impairment in Schizophrenia
• Co- Principle Investigator (Dr. Goldman)
  Eight Week, Double Blind, 3-Arm Parallel, Placebo-Controlled, Randomized Efficacy And Safety Trial Of Atomoxetine, Atomoxetine Plus Buspirone, And Placebo In Adults With Attention Deficit Hyperactivity Disorder.  (2007–2008)

Teaching

• Clinical Neuropsychology Internship and Externship Training Program
• Neuropsychology Case Conference
• Neuroscience Series
• Neuroanatomy Series
• PS305: Neuropsychology Clerkship

Society Memberships

• Member, American Psychological Association (APA)
• Member, Int’l Neuropsychological Society (INS) — Education Action Committee (EAC)
• Past President, Association of Internship Training in Clinical Neuropsychology )AITCN)
• Member, Midwest Neuropsychology Group (MNG)

Selected Recent Publications

• Mohile SG, Lacy M, Rodin M, Bylow K, Dale W, Meager MR, Stadler WM. (2009) Cognitive effects of androgen deprivation therapy in an older cohort of men with prostate cancer. Crit. Rev. Oncol. Hemo.
• Lacy, M., Oliveira, M., Austria, E., & Frim., D. (2009). Neurocognitive Outcome after Endoscopic Third Ventriculocisternostomy in patients with obstructive hydrocephalus. Journal of the International Neuropsychological Society May;15(3):394-8
• Lacy, M., Pyykkonen, B., Hunter, S.J., Do, T., Oliveira, M., Mottlow, D., Austria, E., Larson, E., & Frim, D.M. (2008) Intellectual functioning in children with early shunted post-hemorrhagic hydrocephalus. Pediatric Neurosurgery
• Ruocco, A, Kunchandy, E., & Lacy, M.  (2009)  Psychopathological conditions in adults and older adults: Neuropsychological perspectives in Principles and Practice of Lifespan Developmental Neuropsychology, Cambridge University Press

Selected Conferences & Presentations

• Preparing for Internship, February, 2009; International Neuropsychological Society
• Neurocognitive Aspects of Congenital Hydrocephalus, June 2009 ; Univ. of Illinois